【2024 ESMO BC】张剑教授解读TNBC:一种方案能否适用于所有患者? 2024年欧洲肿瘤内科学会乳腺癌年会(2024 ESMO BREAST CANCER Annual Congress)已于德国柏林圆满落幕。在这次盛会的教育专场中,来自剑桥大学肿瘤学系的Helena Earl教授就“TNBC...
2,Azim HA, Niman S, Partridge AH et al. Breastfeeding in women with hormone receptor-positive breast cancer who conceived after temporary interruption of endocrine therapy: Results from the POSITIVE trial. Abstract 1814O. presented...
2、Nederlof I, et al. Neoadjuvant nivolumab/relatlimab or nivolumab/ipilimumab in triple negative breast cancer with high tumor-infiltrating lymphocytes (TILs). ESMO Congress 2024, LBA11 来源: https://dailyreporter.esmo.org/esmo-congress-2024/breast-cancer/early-stage-immunotherapy-significantly-prol...
2、Nederlof I, et al. Neoadjuvant nivolumab/relatlimab or nivolumab/ipilimumab in triple negative breast cancer with high tumor-infiltrating lymphocytes (TILs). ESMO Congress 2024, LBA11 来源: https://dailyreporter.esmo.org/esmo-congress-2024/breast-cancer/early-stage-immunotherapy-significantly-prol...
Trivedi MS, et al. Rates of pathologic complete response after datopotamab deruxtecan plus durvalumab in the neoadjuvant setting: Results from the I-SPY 2.2 trial. ESMO Congress 2024, LBA15 来源: https://dailyreporter.esmo.org/esmo-congress-2024/breast-cancer/taxane-and-anthracycline-sparing-...
2、Nederlof I, et al. Neoadjuvant nivolumab/relatlimab or nivolumab/ipilimumab in triple negative breast cancer with high tumor-infiltrating lymphocytes (TILs). ESMO Congress 2024, LBA11 来源: https://dailyreporter.esmo.org/esmo-congress-2024/breast-cancer/early-stage-immunotherapy-significantly-prol...
[1]Dieci MV,et al.TILs and overall survival (OS) in HER2+ early breast cancer (eBC): 10-year (yr) updated analysis of the ShortHER trial. Presented at: 2024 ESMO Congress; September 13-17, 2024; Barcelona, Spain. Abstract 239MO. ...
2024年欧洲肿瘤内科学会乳腺癌年会(2024 ESMO BREAST CANCER Annual Congress)将于5月15日至17日(CEST)在德国柏林会展中心举行。目前,一些备受期待的口头报告摘要已经提前揭晓。本文整理了一篇MORPHEUS-pan BC研究中“免疫+ADC”在局部晚期/转移性三阴性乳腺癌(LA/mTNBC)患者中应用的结果。
The ESMO Congress is the most influential oncology platform designed in Europe for clinicians, researchers, patient advocates, journalists and healthcare industry representatives from all over the world. ESMO Congress 2024 will again present the very latest advances in the treatment of cancer and offer...
The ESMO Congress is the most influential oncology platform designed in Europe for clinicians, researchers, patient advocates, journalists and healthcare industry representatives from all over the world. ESMO Congress 2024 will again present the very latest advances in the treatment of cancer and offer...